Valeant Pharmaceuticals

Uk Market News | December 16, 2016

On Thursday Morgan Stanley downgraded its target price on Valeant Pharmaceuticals (NYSE:VRX) shares issuing the company with a ‘Equal-Weight’ rating....

Pharmaceuticals | January 04, 2017

Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that the Board of Directors has elected Richard (Dick) U. DeSchutter to serve as a director, effective January 2, 2017. With the addition of Mr. DeSchutter, Valeant has increased the size of its Board to 13 members, 12 of whom are independent....

Learn Bonds | January 16, 2017

Forging into 2017, analysts continue to cite Valeant Pharmaceutical Intl. Inc.’s (NYSE:VRX) debt, public image and reduced influence among its biggest challenges. The drug maker is now set on regaining portions of the confidence it lost during the last two years. Valeant shares rose to great peaks back in July 2015. A number of setbacks have since gradually chipped away at its all-time highs, and persist to the current day....

Smarter analyst | February 27, 2017

Valeant Pharmaceuticals Intl Inc (NYSE:VRX) announced that it has rapidly scaled up its sales force by nearly 40 percent, effective immediately. “This is a demonstration of our commitment to GI and its relative importance to the broader value of our company,” said Joseph C. Papa, Chairman and CEO of Valeant. “The significant investments in Salix’s dedicated Primary Care Physician (PCP) sales force will help us further reach patients in need of irritable bowel syndrome with diarrhea (IBS-D) trea...